seen from T1
seen from Brazil
seen from United States
seen from United States
seen from Türkiye
seen from South Africa
seen from China
seen from United States
seen from T1
seen from United States
seen from Türkiye
seen from United States
seen from Türkiye
seen from Poland
seen from Poland
seen from Brazil
seen from Russia
seen from Ecuador
seen from United States
seen from Türkiye
Through simplifying and mobilizing SAP, Liquid UI assists businesses of all sizes and sectors to accomplish their specific corporate objectives. Look at our customer quotes only at https://www.guixt.com/company/customers?Referrer=TB-21July23
Anifrolumab
(Heavy chain)EVQLVQSGAE VKKPGESLKI SCKGSGYIFT NYWIAWVRQM PGKGLESMGI IYPGDSDIRYSPSFQGQVTI SADKSITTAY LQWSSLKASD TAMYYCARHD IEGFDYWGRG TLVTVSSASTKGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLYSLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APEFEGGPSVFLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTYRVVSVLTVLH QDWLNGKEYK CKVSNKALPA SIEKTISKAK GQPREPQVYT…
View On WordPress
US FDA accepts first biologics license application for durvalumab of AstraZeneca for the treatment of patients with bladder cancer
US FDA accepts first biologics license application for durvalumab of AstraZeneca for the treatment of patients with bladder cancer
9 December 2016
AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the US Food and Drug Administration (FDA) has accepted the first Biologics License Application (BLA) for durvalumab, a PD-L1 human monoclonal antibody (mAb). FDA has also granted priority review status with a Prescription Drug User Fee Act (PDUFA) set for the second quarter of 2017.
View On WordPress
Know the Facts: Respiratory Syncytial Virus (RSV)
Respiratory Syncytial Virus (RSV) Can Be Dangerous #RSVawareness #PreemieProtection #spon
This is part of a sponsored collaboration with AstraZeneca and DiMe Media. However, all opinions expressed are my own.
There is a good chance that you have heard of Respiratory Syncytial Virus (RSV), especially if you have followed me for a while. You already know some of the facts that I am going to share with you but it is always good to have a refresher. Respiratory Syncytial Virus or RSV is…
View On WordPress
at #JPM16 - Moderna Therapeutics turns away an extra $200 million: with AstraZeneca (collaboration) & with Merck ($100 million investment)
at #JPM16 – Moderna Therapeutics turns away an extra $200 million: with AstraZeneca (collaboration) & with Merck ($100 million investment)
at #JPM16 – Moderna Therapeutics turns away an extra $200 million: with AstraZeneca (collaboration) & with Merck ($100 million investment)
Reporter: Aviva Lev-Ari, PhD, RN
per SOURCES quoted:
AstraZeneca, for one, has sent an important validating signal to outsiders by continuing to invest in 29 Moderna drug candidates at last count. The financial community can’t get enough. As ambitious as…
View On WordPress
5 Questions For MedImmune's Jallal On The Right Culture And Staying Open To Collaboration
Scrip caught up with Dr. Bahija Jallal, AstraZeneca's executive vice-president and head of subsidiary MedImmune, at BIO Europe 2015, in Munich Germany, to discuss challenges ahead for pharma and biotech firms, how business models are evolving to focus on culture not just size and why collaboration is the gateway to innovation.
1. What is your opinion on in-house innovation vs. acquisitions for new technologies?
Bahiji Jallal: We manage not to have this 'not invented here' syndrome at MedImmune and this is really important. At the heart of what we do is definitely science, and science is always about looking to the outside, it's about peer reviewing, sharing and everything else. So for me it's about collaboration; innovative development is about looking outside of our four walls. This is extremely important not just for the company but for the scientists to be able to continue being the best at what they do.
2. Are biotech companies under as much pressure to constantly invest and seek new technologies/programs?
BJ: It depends on the company. The essence behind that is you have to know your strength and you have to focus on what you do best, but at the same time you have to leave space for science that is going to be important 10 years from now. If you have the luxury to be able to invest in both current programs and science for the future, then you have the best of best worlds. You can focus on what you can do now and reinvent the future too.
3: What are the biggest challenges 2016 might present for MedImmune and how it will combat these disruptions?
BJ: I like to look at all challenges as opportunities. Being in drug development is not for the faint of heart. You have to be resilient and entrepreneurial and the most important thing is to learn from any setbacks. This is drug development – you are always going to have ups and downs but the most important thing is how you come up again from the down times. I don’t see next year as being any different in these terms.
4. Looking at the wider industry, what new developments might disrupt the way biotech and pharma firms do business?
BJ: The industry is in an interesting spot right now. I see more innovation coming and more collaboration – which needs to be applauded. Last year there were a record number of new drugs approved by the US FDA and a lot of these were the product of strong collaborations. At the same time we have several challenges we need to embrace and deal with. One is how we can even faster embrace technology, it is moving at such a speed. For example e-health, we need to look at how this is developing and how we can change the way we currently do things. I'm a very impatient person and R&D still takes too long for me. I hope new technological developments will help speed up areas of research and drug development.
We also need to look at telling our story differently. Right now it is all about cost and not developments. Really the industry needs to start showing that we are part of the solution not part of the problem. Along with this, we know that healthcare systems all over the world are under a lot of pressure and so we need to be sitting at the table helping to figure those issues out. We are just one part of that equation though, not the whole thing.
5. You are on a panel at BIO-Europe discussing how big pharma is operating more like biotech firms do. Can you say a bit about this for people not in attendance? What do you mean?
BJ: When we think about the business we are in at the heart of it is science and science thrives when you have what I call a specific formula: it starts with people, you have to have excellent scientists there is no compromise there. But then it is also the environment you create for these scientists and the research to flourish. I don't think this side, the working environment, was paid attention to in the old business model where it was more about how to increase, how to be bigger. But the business culture has to be right for the scientists to be able to collaborate, to be open to the outside and for their creativity to evolve. It's not about size, if you focus on why we are here it's about science and it's about patients, so you have to create an environment to fit that. Whether you are big or small it has to be an environment conducive to creativity.
So... where do I start? I’ve always wanted to run a personal blog, but never really got around to making and maintaining one. I guess I’m mostly excited because now that I’m done with high school, I’ll actually have interesting things to blog about! I’ll be interning at MedImmune for the majority of this summer, and hope to blog about the entire experience. Then, I’ll be a freshman at UMD in the fall, and honestly could not be more excited about that. Follow along for an insider’s view of all to come!
